About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Renal Biomarkers Market Size, Analysis, Drivers, Challenges, and Opportunities
Renal Biomarkers Market

Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarker Type (Functional Biomarker, Up-regulated Protein, Other Biomarker Types), By Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Colorimetric Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass, Spectrometry (LC-MS)), By End-User (Hospital, Diagnostic Laboratory, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54511DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Renal Biomarkers Market Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    5. U.S.
      1. By Biomarker Type
        1. Introduction
          1. Biomarker Type By Value
        2. Functional Biomarker
          1. By Value
        3. Up-regulated Protein
          1. By Value
        4. Other Biomarker Types
          1. By Value
      2. By Diagnostic Technique
        1. Introduction
          1. Diagnostic Technique By Value
        2. Enzyme-linked Immunosorbent Assay
          1. By Value
        3. Colorimetric Assay
          1. By Value
        4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
          1. By Value
        5. Chemiluminescent Enzyme Immunoassay (CLIA)
          1. By Value
        6. Liquid Chromatography Mass
          1. By Value
        7. Spectrometry (LC-MS)
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital
          1. By Value
        3. Diagnostic Laboratory
          1. By Value
        4. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    5. U.K.
      1. By Biomarker Type
        1. Introduction
          1. Biomarker Type By Value
        2. Functional Biomarker
          1. By Value
        3. Up-regulated Protein
          1. By Value
        4. Other Biomarker Types
          1. By Value
      2. By Diagnostic Technique
        1. Introduction
          1. Diagnostic Technique By Value
        2. Enzyme-linked Immunosorbent Assay
          1. By Value
        3. Colorimetric Assay
          1. By Value
        4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
          1. By Value
        5. Chemiluminescent Enzyme Immunoassay (CLIA)
          1. By Value
        6. Liquid Chromatography Mass
          1. By Value
        7. Spectrometry (LC-MS)
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital
          1. By Value
        3. Diagnostic Laboratory
          1. By Value
        4. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    5. China
      1. By Biomarker Type
        1. Introduction
          1. Biomarker Type By Value
        2. Functional Biomarker
          1. By Value
        3. Up-regulated Protein
          1. By Value
        4. Other Biomarker Types
          1. By Value
      2. By Diagnostic Technique
        1. Introduction
          1. Diagnostic Technique By Value
        2. Enzyme-linked Immunosorbent Assay
          1. By Value
        3. Colorimetric Assay
          1. By Value
        4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
          1. By Value
        5. Chemiluminescent Enzyme Immunoassay (CLIA)
          1. By Value
        6. Liquid Chromatography Mass
          1. By Value
        7. Spectrometry (LC-MS)
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital
          1. By Value
        3. Diagnostic Laboratory
          1. By Value
        4. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    5. UAE
      1. By Biomarker Type
        1. Introduction
          1. Biomarker Type By Value
        2. Functional Biomarker
          1. By Value
        3. Up-regulated Protein
          1. By Value
        4. Other Biomarker Types
          1. By Value
      2. By Diagnostic Technique
        1. Introduction
          1. Diagnostic Technique By Value
        2. Enzyme-linked Immunosorbent Assay
          1. By Value
        3. Colorimetric Assay
          1. By Value
        4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
          1. By Value
        5. Chemiluminescent Enzyme Immunoassay (CLIA)
          1. By Value
        6. Liquid Chromatography Mass
          1. By Value
        7. Spectrometry (LC-MS)
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital
          1. By Value
        3. Diagnostic Laboratory
          1. By Value
        4. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Biomarker Type
      1. Introduction
        1. Biomarker Type By Value
      2. Functional Biomarker
        1. By Value
      3. Up-regulated Protein
        1. By Value
      4. Other Biomarker Types
        1. By Value
    3. By Diagnostic Technique
      1. Introduction
        1. Diagnostic Technique By Value
      2. Enzyme-linked Immunosorbent Assay
        1. By Value
      3. Colorimetric Assay
        1. By Value
      4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
        1. By Value
      5. Chemiluminescent Enzyme Immunoassay (CLIA)
        1. By Value
      6. Liquid Chromatography Mass
        1. By Value
      7. Spectrometry (LC-MS)
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospital
        1. By Value
      3. Diagnostic Laboratory
        1. By Value
      4. Others
        1. By Value
    5. Brazil
      1. By Biomarker Type
        1. Introduction
          1. Biomarker Type By Value
        2. Functional Biomarker
          1. By Value
        3. Up-regulated Protein
          1. By Value
        4. Other Biomarker Types
          1. By Value
      2. By Diagnostic Technique
        1. Introduction
          1. Diagnostic Technique By Value
        2. Enzyme-linked Immunosorbent Assay
          1. By Value
        3. Colorimetric Assay
          1. By Value
        4. Particle-enhanced Turbidimetric Immunoassay (PETIA)
          1. By Value
        5. Chemiluminescent Enzyme Immunoassay (CLIA)
          1. By Value
        6. Liquid Chromatography Mass
          1. By Value
        7. Spectrometry (LC-MS)
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospital
          1. By Value
        3. Diagnostic Laboratory
          1. By Value
        4. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Renal Biomarkers Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Abbott
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. BioPorto Diagnostics AS
    3. F. Hoffmann-La Roche AG
    4. BioMerieux
    5. Nexelis (Pacific Biomarkers)
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Biomarkers Market Size The global biomarkers market size was valued at USD 89.81 billion in 2024 and is projected to reach from USD 101.37 billion in 2025 to USD 267.22 billion by 2033, growing at a CAGR of 12.88% 
Buy Now
Global Report
The global cancer biomarker market size was valued at USD 15.86 billion in 2023. It is estimated to reach USD 55.57 billion by 2032, growing at a CAGR of 14.95% during the forecast period (2024–2032). The global cancer biomarker market is prima
Buy Now
Global Report
The global cardiac biomarkers market size was valued at USD 14.73 billion in 2022. It is estimated to reach USD 48.66 billion by 2031, growing at a CAGR of 14.2% during the forecast period (2023–2031). Cardiac biomarkers are substances th
Buy Now
Global Report
Digital Biomarkers Market Size The global digital biomarkers market size was valued at USD 3.43 billion in 2023 and is projected to reach USD 49.17 billion by 2032, growing at a CAGR of 34.43% during the forecast period (2024–2032). In recent years,
Buy Now
Global Report
Neurological Biomarkers Market Size The global neurological biomarkers market size was valued at USD 9.93 billion in 2024 and is projected to reach from USD 11.18 billion in 2025 to USD 32.70 billion by 2033, growing at a CAGR of 12.66% during the f
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.